Bedbugs and consultants are bleeding us dry
Tirofiban can be used to treat STEMI, study shows
Tirofiban, manufactured under the trade name Aggrastat by MSD, is only currently licensed in the UK for use in treatment of non-STEMI patients.
Findings from the three-year open-label trial of 745 patients with STEMI in Italy, Spain and Argentina showed at least 50% recovery from ST-elevation in 85.3% and 83.6% of patients in tirofiban and abciximab groups respectively.
Tirofiban was administered at first medical contact before arterial or sheath insertion, as a bolus of 25 ug/kg followed by an 18-24 hour infusion at 0.15 ug/kg/min.
After a follow-up period of eight months, the incidence of major adverse cardiac events was approximately 20% lower in patients treated with tirofiban compared with abciximab (9.8% compared with 12.4%).
Findings were presented at the 57th Annual Scientific Session of the American College of Cardiology and were published online by the Journal of the American Medical Association (JAMA).
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.